Evidence map›Paper›PMID 39908130›Full record

ArticleInvestigative ophthalmology & visual science2025

Characterizing the Genetic Basis for Inherited Retinal Disease: Lessons Learned From the Foundation Fighting Blindness Clinical Consortium's Gene Poll.

Kari Branham, Lassana Samarakoon, Isabelle Audo, Allison R Ayala, Janet K Cheetham, Stephen P Daiger, Patty Dhooge, Jacque L Duncan, Todd A Durham, Abigail T Fahim and 15 more

Erratum issuedAbstract readMulticenter Study
In one paragraph

Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. The Genetic Landscape of Inherited Retinal Diseases in the Israeli Population.Investigative ophthalmology & visual science · 2026
    Article
  6. Review
  7. Article
  8. Experimental biology and medicine (Maywood, N.J.) · 2026
    Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Kari BranhamUniversity of Michigan, Kellogg Eye Center, Department of Ophthalmology and Vision Sciences, Ann Arbor, Michigan, United States.
Lassana SamarakoonJaeb Center for Health Research, Tampa, Florida, United States.
Isabelle AudoInstitut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France.
Allison R AyalaJaeb Center for Health Research, Tampa, Florida, United States.
Janet K CheethamFoundation Fighting Blindness, Columbia, Maryland, United States.
Stephen P DaigerThe University of Texas, Health Science Center, Houston, Texas, United States.
Patty DhoogeRadboud University, Nijmegen, the Netherlands.
Jacque L DuncanUniversity of California, San Francisco, San Francisco, California, United States.
Todd A DurhamFoundation Fighting Blindness, Columbia, Maryland, United States.
Abigail T FahimUniversity of Michigan, Kellogg Eye Center, Department of Ophthalmology and Vision Sciences, Ann Arbor, Michigan, United States.
Rachel M HuckfeldtMass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Robert B HufnagelCenter for Integrated Healthcare Research, Kaiser Permanente, Honolulu, Hawaii, United States.
Susanne KohlInstitute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.
Ramiro S MaldonadoDuke University Eye Center, Durham, North Carolina, United States.
Michele MeliaJaeb Center for Health Research, Tampa, Florida, United States.
Michel MichaelidesMoorfields Eye Hospital, London, United Kingdom.
Mark E PennesiCasey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States.
José-Alain SahelInstitut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France.
Juliana M Ferraz SallumFederal University of São Paulo, São Paulo, Brazil.
Mandeep S SinghWilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States.
Dror SharonDepartment of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Kimberly StepienDepartment of Ophthalmology & Visual Sciences, University of WI School of Medicine and Public Health, Madison, Wisconsin, United States.
Kaylie JonesRetina Foundation of the Southwest, Dallas, Texas, United States.
Christina Y WengBaylor College of Medicine, Houston, Texas, United States.
Foundation Fighting Blindness Clinical Consortium Investigator Group

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAMBA, DEEPAK ASHOK · 1985 to 2024
$16.8M
NEI NIH HHS P30 EY002162
6 · The paper itself

Abstract

Purpose: The Foundation Fighting Blindness (FFB) Consortium is a collaboration of 41 international clinical centers that manage patients affected with inherited retinal diseases (IRDs). The annual Consortium gene poll was initiated in 2020 to capture the genetic cause of disease in patients with IRD and associated clinical practices of Consortium sites. Data from the 2022 gene poll are reported here. Methods: In 2022, academic, private practice, and government ophthalmology clinics that are members of the Consortium centers were polled to identify per-case IRD genetic causality from a list of 387 syndromic and nonsyndromic IRD genes. The survey also assessed how genetic testing was obtained and clinical practices of the sites. Results: Thirty centers responded and reported genetic data from 33,834 patients (27,561 families). Disease-causing variants were reported in 293 of 387 genes. The most common genetic etiologies were ABCA4 (17%), USH2A (9%), RPGR (6%), PRPH2 (5%), and RHO (4%). The top 100 genes accounted for the genetic cause of disease in 94.4% of patients. Two-thirds of the centers had at least one genetic counselor. In the 21 US sites, genetic testing was commonly obtained through sponsored programs (95%, FFB-My Retina Tracker Programs or Spark-ID Your IRD), whereas in the 9 non-US sites, genetic testing was commonly obtained using either patient- or public health system-funded testing pipelines. Clinical work-up of patients with IRD most commonly included updating history, eye examination, and optical coherence tomography. Conclusions: This report provides the largest assessment of genetic causality in the IRD patient population across multiple continents to date.

Indexed as

BlindnessRetinal DiseasesFoundationsGenetic TestingHumansSurveys and Questionnaires

Identifiers

PMID39908130
PMCPMC11804890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.